Company intelligence / Profile preview
Titan Pharmaceuticals, Inc.
- Ownership
- Public · TTNP
- Employees
- ~4
- Development stage
- Other
Overview
Titan Pharmaceuticals developed the FDA-approved Probuphine® implant for maintenance treatment of opioid use disorder but discontinued U.S. commercialization in late 2020 and sold related assets in September 2023. The company now focuses on developing new therapeutics using its proprietary ProNeura® subdermal implant platform targeting chronic diseases such as substance use disorders, chronic pruritus, Parkinson's disease, hypothyroidism, and others. Its current pipeline includes a nalmefene implant for prevention of opioid relapse post-detoxification and other early-stage programs.
- Therapeutic areas
- NeurologyEndocrinologyPsychiatryDermatology
- Modalities
- Subdermal drug implantsSmall molecules
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Titan Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Titan Pharmaceuticals, Inc..